The Experts below are selected from a list of 324 Experts worldwide ranked by ideXlab platform
Adolfo Sebastiani - One of the best experts on this subject based on the ideXlab platform.
-
prevalence of factor xiii val34leu polymorphism in patients affected by spontaneous Subconjunctival Hemorrhage
American Journal of Ophthalmology, 2004Co-Authors: Francesco Parmeggiani, Ciro Costagliola, Carlo Incorvaia, Donato Gemmati, Sergio Dangelo, Silvia Tognazzo, Gian L Scapoli, Adolfo SebastianiAbstract:Abstract Purpose To verify the prevalence of Val34Leu polymorphism in factor XIII A-chain gene (FXIII Val34Leu) in patients with spontaneous Subconjunctival Hemorrhage (SCH). Design Nonrandomized case-control study. Methods One hundred seven white patients suffering from one or more episodes of idiopathic SCH and 107 healthy subjects were matched for age and gender, and genotyped for FXIII Val34Leu. Anamnestic, ophthalmologic, cardiovascular, and serologic examinations were performed. Results Frequency of FXIII mutated allele (Leu34) was significantly higher in SCH patients than in controls. Computing together heterozygotes (Val/Leu) and homozygotes (Leu/Leu), genotype distribution was statistically different. In a conditional logistic regression model, the comparison of the three separated genotypes, performed among 25 patients with recurrent idiopathic SCHs and controls, gave significant differences for both Val/Leu and Leu/Leu variables. Conclusion Both homozygosity and heterozygosity for FXIII Val34Leu predispose to idiopathic SCH, emphasizing the role of Leu34 allele as inherited risk factor for spontaneous, especially recurrent, SCHs.
-
recurrent episodes of spontaneous Subconjunctival Hemorrhage in patients with factor xiii val34leu mutation
American Journal of Ophthalmology, 2002Co-Authors: Carlo Incorvaia, Francesco Parmeggiani, Ciro Costagliola, Donato Gemmati, Gian L Scapoli, Adolfo SebastianiAbstract:Abstract Purpose To report on the occurrence of frequent episodes of spontaneous Subconjunctival Hemorrhage (SCH) in patients with the Leu 34 allele of the coagulation factor XIII (FXIII), known to be associated with high hemorrhagic risk. Design Observational case series. Methods Five young adults who had suffered from recurrent idiopathic SCH not associated with any recognized ocular and systemic hemorrhagic risk factor were investigated. Accurate anamnestic, ophthalmologic, hematologic, and serologic examinations were performed, together with blood pressure measurements, electrocardiogram (ECG), and 24-hour Holter ECG recordings. FXIII Val34Leu polymorphism was studied by DNA chain polymerase reaction. Results DNA analyses showed that the hemorrhagic mutated Leu34 allele was present in four of our selected patients: two mutated homozygotes (Leu/Leu) and two heterozygotes (Val/Leu). In the last subject this polymorphism was not detected. All the other clinical evaluations did not disclose any significant abnormality. Conclusions The FXIII Val34Leu mutation may be associated with an increased risk for spontaneous episodes of SCH.
Mirko R Jankov - One of the best experts on this subject based on the ideXlab platform.
-
the effect of topical apraclonidine on Subconjunctival Hemorrhage and flap adherence in lasik patients
American Journal of Ophthalmology, 2006Co-Authors: Ioannis M Aslanides, Nikolaos S Tsiklis, Efekan Ozkilic, Efekan Coskunseven, Ioannis G Pallikaris, Mirko R JankovAbstract:PURPOSE: To determine whether the use of topical apraclonidine just before the LASIK procedure prevents Subconjunctival Hemorrhage and to study its effect on postoperative fl ap adherence. METHODS: Topical apraclonidine 0.125% was randomly applied to 1 eye of 66 myopic patients who underwent primary bilateral LASIK. Apraclonidine was instilled 1 hour prior to and 30 seconds just before placing the vacuum ring of the microkeratome, whereas the other eye served as control. Thirty minutes after the operation, all patients were examined by the surgeon to evaluate hyperemia and identify fl ap-related complications (eg, slippage, dislocation, or fl ap folds). The size of Subconjunctival Hemorrhage was also evaluated on postoperative days 1 and 7. All 132 eyes in the study were examined after surgery to identify fl ap folds and/or their dislocation. RESULTS: In the apraclonidine group, 48 (72.8%) eyes had no hyperemia, 16 (24.2%) eyes had mild hyperemia, 2 (3%) eyes had moderate hyperemia, and no (0%) eyes had severe hyperemia. In the control group, 37 (56.1%) eyes had mild hyperemia, 21 (31.8%) eyes had moderate hyperemia, 1 (1.5%) eye had severe hyperemia, and 7 (10.6%) eyes had no hyperemia. In the apraclonidine group, 44 (66.7%) eyes had no Subconjunctival Hemorrhage (grade 0); grade 1 was present in 19 (28.8%) eyes whereas grades 2 and 3 were present in 2 (3%) eyes and 1 (1.5%) eye, respectively. In the control group, 19 (28.8%) eyes showed grade 0, 13 (19.7%) eyes had grade 1, and grades 2 and 3 were present in 20 (30.3%) eyes and 14 (21.2%) eyes, respectively. Chi-square test showed a highly signifi cant difference between the two groups (P� .001). No fl aprelated problems were reported in either group. CONCLUSIONS: Topical apraclonidine applied before LASIK surgery may prevent immediate postoperative hyperemia and prolonged Subconjunctival Hemorrhage by its alpha-mimetic vasoconstrictor effect without inducing fl ap adherence complication. [J Refract Surg. 2006;22:xxx-xxx.] L
-
the effect of topical apraclonidine on Subconjunctival Hemorrhage and flap adherence in lasik patients
Journal of Refractive Surgery, 2006Co-Authors: Loannis M Aslanides, Nikolaos S Tsiklis, Efekan Ozkilic, Efekan Coskunseven, Loannis C Pallikaris, Mirko R JankovAbstract:PURPOSE To determine whether the use of topical apraclonidine just before the LASIK procedure prevents Subconjunctival Hemorrhage and to study its effect on postoperative flap adherence. METHODS Topical apraclonidine 0.125% was randomly applied to 1 eye of 66 myopic patients who underwent primary bilateral LASIK. Apraclonidine was instilled 1 hour prior to and 30 seconds before placing the vacuum ring of the microkeratome, whereas the other eye served as control. Thirty minutes after the operation, all patients were examined by the surgeon to evaluate hyperemia and identify flap-related complications (eg, slippage, dislocation, or flap folds). The size of Subconjunctival Hemorrhage was also evaluated on postoperative days 1 and 7. All 132 eyes in the study were examined after surgery to identify flap folds and/or their dislocation. RESULTS In the apraclonidine group, 48 (72.8%) eyes had no hyperemia, 16 (24.2%) eyes had mild hyperemia, 2 (3%) eyes had moderate hyperemia, and no (0%) eyes had severe hyperemia. In the control group, 37 (56.1%) eyes had mild hyperemia, 21 (31.8%) eyes had moderate hyperemia, 1 (1.5%) eye had severe hyperemia, and 7 (10.6%) eyes had no hyperemia. In the apraclonidine group, 44 (66.7%) eyes had no Subconjunctival Hemorrhage (grade 0); grade 1 was present in 19 (28.8%) eyes whereas grades 2 and 3 were present in 2 (3%) eyes and 1 (1.5%) eye, respectively. In the control group, 19 (28.8%) eyes showed grade 0, 13 (19.7%) eyes had grade 1, and grades 2 and 3 were present in 20 (30.3%) eyes and 14 (21.2%) eyes, respectively. Chi-square test showed a highly significant difference between the two groups (P < .001). No flap-related problems were reported in either group. CONCLUSIONS Topical apraclonidine applied before LASIK surgery may prevent immediate postoperative hyperemia and prolonged Subconjunctival Hemorrhage by its alpha-mimetic vasoconstrictor effect without inducing flap adherence complication.
Francesco Parmeggiani - One of the best experts on this subject based on the ideXlab platform.
-
prevalence of factor xiii val34leu polymorphism in patients affected by spontaneous Subconjunctival Hemorrhage
American Journal of Ophthalmology, 2004Co-Authors: Francesco Parmeggiani, Ciro Costagliola, Carlo Incorvaia, Donato Gemmati, Sergio Dangelo, Silvia Tognazzo, Gian L Scapoli, Adolfo SebastianiAbstract:Abstract Purpose To verify the prevalence of Val34Leu polymorphism in factor XIII A-chain gene (FXIII Val34Leu) in patients with spontaneous Subconjunctival Hemorrhage (SCH). Design Nonrandomized case-control study. Methods One hundred seven white patients suffering from one or more episodes of idiopathic SCH and 107 healthy subjects were matched for age and gender, and genotyped for FXIII Val34Leu. Anamnestic, ophthalmologic, cardiovascular, and serologic examinations were performed. Results Frequency of FXIII mutated allele (Leu34) was significantly higher in SCH patients than in controls. Computing together heterozygotes (Val/Leu) and homozygotes (Leu/Leu), genotype distribution was statistically different. In a conditional logistic regression model, the comparison of the three separated genotypes, performed among 25 patients with recurrent idiopathic SCHs and controls, gave significant differences for both Val/Leu and Leu/Leu variables. Conclusion Both homozygosity and heterozygosity for FXIII Val34Leu predispose to idiopathic SCH, emphasizing the role of Leu34 allele as inherited risk factor for spontaneous, especially recurrent, SCHs.
-
recurrent episodes of spontaneous Subconjunctival Hemorrhage in patients with factor xiii val34leu mutation
American Journal of Ophthalmology, 2002Co-Authors: Carlo Incorvaia, Francesco Parmeggiani, Ciro Costagliola, Donato Gemmati, Gian L Scapoli, Adolfo SebastianiAbstract:Abstract Purpose To report on the occurrence of frequent episodes of spontaneous Subconjunctival Hemorrhage (SCH) in patients with the Leu 34 allele of the coagulation factor XIII (FXIII), known to be associated with high hemorrhagic risk. Design Observational case series. Methods Five young adults who had suffered from recurrent idiopathic SCH not associated with any recognized ocular and systemic hemorrhagic risk factor were investigated. Accurate anamnestic, ophthalmologic, hematologic, and serologic examinations were performed, together with blood pressure measurements, electrocardiogram (ECG), and 24-hour Holter ECG recordings. FXIII Val34Leu polymorphism was studied by DNA chain polymerase reaction. Results DNA analyses showed that the hemorrhagic mutated Leu34 allele was present in four of our selected patients: two mutated homozygotes (Leu/Leu) and two heterozygotes (Val/Leu). In the last subject this polymorphism was not detected. All the other clinical evaluations did not disclose any significant abnormality. Conclusions The FXIII Val34Leu mutation may be associated with an increased risk for spontaneous episodes of SCH.
Carlo Incorvaia - One of the best experts on this subject based on the ideXlab platform.
-
prevalence of factor xiii val34leu polymorphism in patients affected by spontaneous Subconjunctival Hemorrhage
American Journal of Ophthalmology, 2004Co-Authors: Francesco Parmeggiani, Ciro Costagliola, Carlo Incorvaia, Donato Gemmati, Sergio Dangelo, Silvia Tognazzo, Gian L Scapoli, Adolfo SebastianiAbstract:Abstract Purpose To verify the prevalence of Val34Leu polymorphism in factor XIII A-chain gene (FXIII Val34Leu) in patients with spontaneous Subconjunctival Hemorrhage (SCH). Design Nonrandomized case-control study. Methods One hundred seven white patients suffering from one or more episodes of idiopathic SCH and 107 healthy subjects were matched for age and gender, and genotyped for FXIII Val34Leu. Anamnestic, ophthalmologic, cardiovascular, and serologic examinations were performed. Results Frequency of FXIII mutated allele (Leu34) was significantly higher in SCH patients than in controls. Computing together heterozygotes (Val/Leu) and homozygotes (Leu/Leu), genotype distribution was statistically different. In a conditional logistic regression model, the comparison of the three separated genotypes, performed among 25 patients with recurrent idiopathic SCHs and controls, gave significant differences for both Val/Leu and Leu/Leu variables. Conclusion Both homozygosity and heterozygosity for FXIII Val34Leu predispose to idiopathic SCH, emphasizing the role of Leu34 allele as inherited risk factor for spontaneous, especially recurrent, SCHs.
-
recurrent episodes of spontaneous Subconjunctival Hemorrhage in patients with factor xiii val34leu mutation
American Journal of Ophthalmology, 2002Co-Authors: Carlo Incorvaia, Francesco Parmeggiani, Ciro Costagliola, Donato Gemmati, Gian L Scapoli, Adolfo SebastianiAbstract:Abstract Purpose To report on the occurrence of frequent episodes of spontaneous Subconjunctival Hemorrhage (SCH) in patients with the Leu 34 allele of the coagulation factor XIII (FXIII), known to be associated with high hemorrhagic risk. Design Observational case series. Methods Five young adults who had suffered from recurrent idiopathic SCH not associated with any recognized ocular and systemic hemorrhagic risk factor were investigated. Accurate anamnestic, ophthalmologic, hematologic, and serologic examinations were performed, together with blood pressure measurements, electrocardiogram (ECG), and 24-hour Holter ECG recordings. FXIII Val34Leu polymorphism was studied by DNA chain polymerase reaction. Results DNA analyses showed that the hemorrhagic mutated Leu34 allele was present in four of our selected patients: two mutated homozygotes (Leu/Leu) and two heterozygotes (Val/Leu). In the last subject this polymorphism was not detected. All the other clinical evaluations did not disclose any significant abnormality. Conclusions The FXIII Val34Leu mutation may be associated with an increased risk for spontaneous episodes of SCH.
Devrim Deniz - One of the best experts on this subject based on the ideXlab platform.
-
the application of continuous positive airway pressure in an obstructive sleep apnea syndrome accompanied by Subconjunctival Hemorrhage secondary to hypertensive episodes a case report
European Respiratory Journal, 2015Co-Authors: B Ozkara, Haldun Sevketbeyoglu, Dilaver Tas, Devrim DenizAbstract:Introduction: Spontaneous Subconjunctival Hemorrhage is a common clinical condition associated with hypertension (HT). Although obstructive sleep apnea syndrome (OSAS) is an independent risk factor for HT, it may cause complications. Case Report: A 60-year-old male patient with no bleeding disorders or antiplatelet treatment history presented with Subconjunctival Hemorrhage after waking up in the morning repeated three times in last two years. He complained of occasional snoring and daytime sleepiness. The body mass index was 30.9 kg/m 2 . He was on antihypertensive medication for 5 years and diagnosed with hypertensive retinopathy by color fundus imaging [figure 1]. A tension Holter monitoring was performed. Day and night rates of systolic and diastolic blood pressures (SBP and DBP) were recorded and classified to be normal, acceptable or critical level [table1]. A polysomnography test revealed OSAS according to apnea-hypopnea index (AHI) to be 45.8. He was given continuous positive airway pressure (CPAP) treatment. After CPAP treatment, tension Holter monitoring showed significantly lower results in SBP, which was 2% at night and 1% at critical level during the day. No recurrence of Subconjunctival Hemorrhage was observed after CPAP treatment. Conclusion: Recurrent Subconjunctival Hemorrhages was considered due to hypertensive episodes caused by OSAS in presented case. Due to preventive effects of CPAP treatment on OSAS at night, it should be taken into consideration in complications of hypertension, such as Subconjunctival Hemorrhage.
